Lipicard Technologies Limited - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lipicard Technologies Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Lipicard Technologies Limited - Product Pipeline Review - 2015', provides an overview of the Lipicard Technologies Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lipicard Technologies Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Lipicard Technologies Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Lipicard Technologies Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Lipicard Technologies Limited's pipeline products

Reason to Buy

- Evaluate Lipicard Technologies Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Lipicard Technologies Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Lipicard Technologies Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Lipicard Technologies Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lipicard Technologies Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Lipicard Technologies Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Lipicard Technologies Limited Snapshot 7
Lipicard Technologies Limited Overview 7
Key Information 7
Key Facts 7
Lipicard Technologies Limited - Research and Development Overview 8
Key Therapeutic Areas 8
Lipicard Technologies Limited - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Lipicard Technologies Limited - Pipeline Products Glance 13
Lipicard Technologies Limited - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 15
Lipicard Technologies Limited - Drug Profiles 16
Gabafol 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
KeraKlear 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
LT-1121 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
LT-1123 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
LT-2121 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
LT-2221 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
LT-2223 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
LT-2321 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
LT-2322 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
LT-2323 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
LT-2421 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
LT-2423 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
LT-2521 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
LT-3121 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
LT-3122 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
LT-4121 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LT-4122 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
LT-4123 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
LT-4124 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LT-4125 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
LT-4126 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
LT-5121 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
LT-5122 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
LT-5221 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
LT-5222 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
LT-5223 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
LT-5321 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
LT-5322 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LT-5323 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
LT-5421 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
LT-5423 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
LT-5521 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Peroxibrate 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Platrol 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Raviprofen 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
LT-6121 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Lipicard Technologies Limited - Pipeline Analysis 52
Lipicard Technologies Limited - Pipeline Products by Target 52
Lipicard Technologies Limited - Pipeline Products by Route of Administration 53
Lipicard Technologies Limited - Pipeline Products by Molecule Type 54
Lipicard Technologies Limited - Pipeline Products by Mechanism of Action 55
Lipicard Technologies Limited - Locations And Subsidiaries 56
Head Office 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

Lipicard Technologies Limited, Key Information 7
Lipicard Technologies Limited, Key Facts 7
Lipicard Technologies Limited - Pipeline by Indication, 2015 9
Lipicard Technologies Limited - Pipeline by Stage of Development, 2015 11
Lipicard Technologies Limited - Monotherapy Products in Pipeline, 2015 12
Lipicard Technologies Limited - Preclinical, 2015 13
Lipicard Technologies Limited - Discovery, 2015 15
Lipicard Technologies Limited - Pipeline by Target, 2015 52
Lipicard Technologies Limited - Pipeline by Route of Administration, 2015 53
Lipicard Technologies Limited - Pipeline by Molecule Type, 2015 54
Lipicard Technologies Limited - Pipeline Products by Mechanism of Action, 2015 55